A detailed history of Fairfield Financial Advisors, LTD transactions in Novo Nordisk A S stock. As of the latest transaction made, Fairfield Financial Advisors, LTD holds 52,068 shares of NVO stock, worth $5.53 Million. This represents 2.11% of its overall portfolio holdings.

Number of Shares
52,068
Previous 48,463 7.44%
Holding current value
$5.53 Million
Previous $6.92 Billion 10.38%
% of portfolio
2.11%
Previous 2.04%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$119.07 - $145.42 $429,247 - $524,239
3,605 Added 7.44%
52,068 $6.2 Billion
Q2 2024

Aug 09, 2024

BUY
$122.71 - $146.91 $5.95 Million - $7.12 Million
48,463 New
48,463 $6.92 Billion
Q4 2023

Nov 04, 2024

BUY
$87.78 - $105.45 $635,966 - $763,985
7,245 Added 23.83%
37,652 $3.9 Billion
Q3 2023

Nov 04, 2024

BUY
$90.94 - $199.54 $1.73 Million - $3.79 Million
18,984 Added 166.19%
30,407 $2.77 Billion
Q2 2023

Nov 04, 2024

SELL
$155.98 - $172.65 $6.34 Million - $7.02 Million
-40,645 Reduced 78.06%
11,423 $1.85 Billion
Q1 2023

Nov 04, 2024

SELL
$132.34 - $159.14 $5.87 Million - $7.06 Million
-44,335 Reduced 85.15%
7,733 $1.22 Billion
Q4 2022

Oct 07, 2024

SELL
$102.55 - $135.33 $40,609 - $53,590
-396 Reduced 5.73%
6,518 $882 Million
Q3 2022

Oct 07, 2024

SELL
$95.28 - $116.93 $3.96 Million - $4.86 Million
-41,549 Reduced 85.73%
6,914 $689 Million
Q2 2022

Oct 07, 2024

SELL
$103.24 - $121.81 $4.38 Million - $5.17 Million
-42,420 Reduced 87.53%
6,043 $673 Million
Q1 2022

Oct 07, 2024

SELL
$93.1 - $112.54 $4.19 Million - $5.06 Million
-44,960 Reduced 92.77%
3,503 $389 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $240B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Fairfield Financial Advisors, LTD Portfolio

Follow Fairfield Financial Advisors, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfield Financial Advisors, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fairfield Financial Advisors, LTD with notifications on news.